Comparative Pharmacology
Head-to-head clinical analysis: LENVIMA versus NERATINIB MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LENVIMA versus NERATINIB MALEATE.
LENVIMA vs NERATINIB MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lenvatinib is a multikinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3), fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3, FGFR4), platelet-derived growth factor receptor alpha (PDGFRα), KIT, and RET. It inhibits angiogenesis, tumor growth, and progression by blocking these receptor tyrosine kinases.
Irreversible inhibitor of human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) tyrosine kinases, leading to inhibition of downstream signaling pathways and tumor cell proliferation.
24 mg orally once daily for differentiated thyroid carcinoma; 18 mg orally once daily plus everolimus 5 mg orally once daily for renal cell carcinoma; 12 mg orally once daily plus pembrolizumab 200 mg intravenously every 3 weeks for endometrial carcinoma; 8 mg orally once daily (or 10 mg for patients with body weight ≥60 kg) plus pembrolizumab 200 mg intravenously every 3 weeks for hepatocellular carcinoma.
240 mg (6 tablets of 40 mg) orally once daily with food, continuously until disease progression or unacceptable toxicity.
None Documented
None Documented
Terminal elimination half-life is approximately 28 hours, supporting once-daily dosing.
Terminal half-life is approximately 7–17 hours (mean 12 hours); this supports twice-daily dosing. Steady-state is achieved within 7 days.
Approximately 71% of the dose is excreted in feces (34% as unchanged drug) and 25% in urine (0.4% as unchanged).
Primarily fecal (approximately 97% of the administered dose recovered in feces as unchanged drug and metabolites); renal excretion is minimal (approximately 1% of the dose recovered in urine).
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor